PR

Public Relations

Press Release

Hugel accelerates the leap forward as a global company Appointing ‘Brent Saunders’, a world-class expert in the medical aesthetic industry
2022-05-19

Hugel accelerates the leap forward as a global company

Appointing ‘Brent Saunders’, a world-class expert in the medical aesthetic industry

 

- Brent Saunders, former Allergan Chairman and CEO, is appointed as a member of the Board of Directors of Hugel

- To be appointed as ‘other non-executive director at the extraordinary general meeting of shareholders in June ... Afterwards, expected to serve as the Chairman of Hugel’s BoD

 

Hugel Co., Ltd. (CEO Son Ji-hoon), a global total medical aesthetics company, held a Board of Directors meeting on the 19th of May. Board resolved to convene an extraordinary general shareholders’ meeting to appoint Brent L. Saunders (the former CEO and Chairman of Allergan, now AbbVie) to the Board as a other non-executive director. Once his appointment is approved by shareholders’ meeting on June 29th, he will serve as the Chairman of Hugel’s Board.

Brent Saunders, nominated for the Board of Directors, is an veteran with 25 years of experience in the pharmaceutical, bio- and healthcare industries, and has been in leadership roles at several prominent global pharmaceutical and healthcare companies In particular, he served as the ▲CEO and Chairman of Allergan (now AbbVie) from 2015 to 2020, leading the global market with products such as ‘Botox’ and ‘Juvéderm’ whilst also being recognized for his leadership in the $63 billion M&A with AbbVie in 2020. In addition, he served as the ▲President of the global consumer division of Schering-Plough; the ▲Chairman of the board and CEO of Bausch + Lomb (a Canadian eye health company); the ▲Chairman of Forest Laboratories (an American pharmaceutical company) and as the ▲CEO of Vesper Health.

 

With the appointment of Brent Saunders, Hugel's efforts towards becoming a leading global medical aesthetics company will further accelerate, particularly benefiting from his rich experience and expertise to help medical aesthetics product portfolio such as botulinum toxin product ‘Letybo’ and filler brands ‘Revolax’ and ‘Dermalax’

 

Michael Keyoung, the head of North America and Korea business of CBC stated “As the Aphrodite Consortium completes the transaction, we have strong confidence in Hugel’s global growth potential. Bringing Brent Saunders is a significant milestone for propelling Hugel towards remarkable and sustainable global growth, further solidifying Hugel’s efforts to advance into the global market.” Michael Keyoung added “Saunders is a medical aesthetics industry legend and his experience compliments Hugel’s globalization effort. CBC trusts Mr. Saunders’ expertise in medical aesthetics is very valuable for Hugel.” 

 

Jihoon Sohn, Hugel’s CEO said, "Brent Saunders, the new Director candidate for Hugel, is known as a 'legendary figure' who has achieved unrivaled results in the global medical aesthetic industry. Together with our new shareholders and Board of Directors and with his expertise and global experience, we plan to become a true leader in the global medical aesthetic industry and prove Hugel's corporate value by providing satisfactory solutions to consumers and practitioners around the world.”

 

Prev Hugel held Extraordinary Meeting of General Shareholders: Brent Saunders, World-class Expert in Medical Aesthetics Joins Hugel’s Global Voyage
Next Hugel reported1Q22revenue of KRW64.9bn and operating profit of KRW25.0bn